Education
About Us
Working with TipRanks
Follow Us
Mediwound (MDWD)
NASDAQ:MDWD
MDWD Stock Chart & Stats
$16.25
-$0.64(-3.70%)
At close: 4:00 PM EST
$16.25
-$0.64(-3.70%)
Day’s Range― - ―
52-Week Range$14.14 - $22.51
Previous CloseN/A
Volume29.05K
Average Volume (3M)83.89K
Market Cap
$208.35M
Enterprise Value$0.00
Total Cash (Recent Filing)$59.09M
Total Debt (Recent Filing)$9.33M
Price to Earnings (P/E)―
Beta1.09
Next Earnings
Mar 12, 2026EPS Estimate
-0.59Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.24
Shares Outstanding12,821,433
10 Day Avg. Volume97,082
30 Day Avg. Volume83,890
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)5.69
Price to Sales (P/S)8.77
P/FCF Ratio-8.91
Enterprise Value/Market Cap0.00
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$30.00Price Target Upside84.62% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
EscharEx Commercial PotentialFavorable health economic analysis combined with ongoing Phase 3 development for EscharEx supports premium pricing potential and a materially larger peak sales opportunity.
Government Contract And BARDA PartnershipA potential BARDA agreement for NexoBrid would secure government procurement and provide development funding for a room-temperature stable formulation and blast trauma evaluation, supporting commercial growth and product development programs.
Manufacturing CapacityCommissioning of an expanded GMP manufacturing facility increases NexoBrid supply capacity roughly sixfold, positioning the company to meet growing global demand and alleviate prior supply constraints.
Bears Say
Clinical And Regulatory RiskClinical trial setbacks or regulatory hurdles for EscharEx or NexoBrid could delay approvals or restrict label expansion, reducing anticipated commercial upside.
Financial Performance And Dilution RiskOngoing operating losses and net losses increase cash burn and raise the likelihood of additional financing that could dilute existing shareholders.
Revenue Timing And Government PaymentsUncertainty around timing of government payments and procurement could push expected product revenue into 2026, weakening near-term revenue visibility and financial planning.
Mediwound News
MDWD FAQ
What was Mediwound’s price range in the past 12 months?
Mediwound lowest stock price was $14.14 and its highest was $22.50 in the past 12 months.
What is Mediwound’s market cap?
Mediwound’s market cap is $208.35M.
When is Mediwound’s upcoming earnings report date?
Mediwound’s upcoming earnings report date is Mar 12, 2026 which is in 53 days.
How were Mediwound’s earnings last quarter?
Mediwound released its earnings results on Nov 20, 2025. The company reported -$0.24 earnings per share for the quarter, beating the consensus estimate of -$0.812 by $0.572.
Is Mediwound overvalued?
According to Wall Street analysts Mediwound’s price is currently Undervalued.
Does Mediwound pay dividends?
Mediwound does not currently pay dividends.
What is Mediwound’s EPS estimate?
Mediwound’s EPS estimate is -0.59.
How many shares outstanding does Mediwound have?
Mediwound has 12,821,433 shares outstanding.
What happened to Mediwound’s price movement after its last earnings report?
Mediwound reported an EPS of -$0.24 in its last earnings report, beating expectations of -$0.812. Following the earnings report the stock price went down -5.599%.
Which hedge fund is a major shareholder of Mediwound?
Currently, no hedge funds are holding shares in MDWD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Mediwound Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$30.00 (84.62% Upside)
$30.00 (84.62% Upside)
Blogger Sentiment
Bullish
MDWD Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 2.2K Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
12.91%
12-Months-Change
Fundamentals
Return on Equity
-48.83%
Trailing 12-Months
Asset Growth
26.35%
Trailing 12-Months
Company Description
Mediwound
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
MDWD Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant advancements in clinical trials and manufacturing capabilities, as well as strong revenue growth. However, these were offset by increased operating losses and uncertainties related to government contracts and clinical trial timelines.View all MDWD earnings summariesMDWD Stock 12 Month Forecast
Average Price Target
$30.00
▲(84.62% Upside)
Technical Analysis
Lineage Therap
―
Eledon Pharmaceuticals
―
Design Therapeutics
―
Ventyx Biosciences
―
Tevogen Bio Holdings
―
Ownership Overview
―
Insiders
5.21% Mutual Funds
28.35% Other Institutional Investors
62.92% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---